Long-term Outcomes After Resection of Primary Duodenal Adenocarcinoma

The aim of this study is to examine the long-term outcomes after curatively intended resection of duodenal adenocarcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Duodenal Cancer Digestive System Diseases Digestive System Neoplasms Duodenal Diseases Duodenal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kristian Schaumburg Kiim

Copenhagen NV, Copenhagen, DK-2400, Denmark

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients subjected to resection of primary duodenal adenocarcinoma

Exclusion criteria

None.

Treatment and study plan

Pancreaduodenectomy and possible adjuvant therapy

Procedure

Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.

Primary outcomes

3-year survival

Time frame: Three years

Cumulative survival after three years

Secondary outcomes

Duodenal cancer recurrence

Time frame: 5 years

Recurrence found by computed tomography scan

Sponsors and collaborators

Lead sponsor

Bispebjerg Hospital

Other

Registry information

Important dates

Study start: 1999
Primary completion: 2020
Study completion: 2021
First posted: Nov 26, 2021
Registry last updated: Nov 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed